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Abstract: Congestive heart failure (CHF) is the fi nal stage in several heart diseases. Th e diagnosis of 
CHF in older patients is a challenge. Preserved left  ventricular systolic function is a characteristic type 
of CHF in seniors.
Th e purpose of the study was to characterize elderly patients with CHF and to highlight specifi c features of 
the conditions in seniors. Th e most common etiology of HF in this group of patients is hypertension and 
coronary heart disease. In seniors atypical presentations of chronic heart failure is much more common 
than in younger patients. Malnutrition, limitations of exercise and sedentary lifestyles or comorbid 
diseases have an infl uence on asymptomatic, early stage of HF. Th ere are better outcomes of treatment in 
obese individuals. It is called the obesity paradox. Open communication with a patient and his/her family 
may improve their response to therapy. When heart failure becomes an incurable disease and aggressive 
treatment is ineff ective, palliative care should be considered in end-of-life heart failure patients. Th e goal 
of treatment in the remaining moments of life last moments of life should be maximizing the patient’s 
comfort.
Key words: congestive heart failure, seniors, palliative care, cachexia.
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Introduction
Congestive heart failure (HF) is the  fi nal stage in several heart diseases (cardiomy-
opathies, valvular or ischemic heart disease and many others) [1]. Reduced in-hospital 
mortality and length of hospital stay in seniors are results of improvement in 
the  treatment of cardiovascular disease, for example, revascularization therapy for 
acute myocardial infarction and strict control of hypertension or eff ective treatment of 
valvular disease [2, 3].
HF is the  leading cause of hospitalization in the  elderly [4–6] and represents 
a  challenging problem to national health problem for the  economy [7]. More than 
half of all patients hospitalized with acute decompensated heart failure are older than 
75 years of age, approximately 20% of these patients are in the very-elderly age group: 
85  years and older [8]. Th e  mean age of the  overall population with HF diff ers in 
various countries. Th is fi nding probably refl ects diff erent life expectancies, specifi c to 
each country. Th e mean age of the overall population with HF, for example, in Poland 
is 69.1 ± 12.3 years (by the Polish ESC-HF Long-Term Registry); in the United States it 
is 73.2 ± 14 years (OPTIMIZE-HF) and in Japan it is 72.9 ± 13.8 years (ATTEND) [9]. 
65 years of age or more is the established defi nition of what is considered an elderly age, 
but the clinical conditions of people aged 65 to 74 have improved. Nowadays, patients 
aged 75 years or older defi ne the group in which the diagnosis of HF increases [9]. It 
seems reasonable to revaluate the threshold of the so-called “older age” [9].
Nevertheless, there are strict criteria for the  diagnosis of HF; unusual clinical 
manifestations and other comorbid conditions in seniors make the  diagnosis more 
challenging [8, 10, 11].
The optimal management of HF in seniors is a  growing health care priority 
because cumulative morbidity, mortality and associated costs escalate as the  aging 
population increases [8].
Previous studies describing the  elderly population suff ering from chronic heart 
failure have indicated that suff erers tend to be female with a preserved left  ventricular 
systolic function [12, 13].
Some studies have shown an underdosage of recommended medications and less 
frequent usage of evidence-based therapies in seniors [14]. Th e  European Society 
of Cardiology does not recommend specific guidelines of treatment for seniors 
with HF [15].
Objectives
Th e purpose of the  study was to characterize the  elderly patients with chronic heart 
failure and to highlight specifi c features of the conditions in seniors.
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Risk factors of chronic heart failure
Several morphological and physiological changes in the  aging population contribute 
to heart failure [16, 17]. Comorbidities and variations at the cellular and the clinico-
pathophysiological level may interact with a  lifelong exposure to the  risk factors of 
cardiac and vascular diseases leading to heart failure [16].
Th e most common etiology of HF is hypertension and coronary heart disease [16, 18].
Jugdutt BI. considered heart failure as “superimposed on an ongoing process”, 
which is oft en described as the  end stage of cardiovascular disease [19]. Studies by 
Gregory A. Nichols has shown that chronic heart failure in diabetic patients is also 
a  common occurrence. Subjects suff ering from diabetes who developed HF diff ered 
from patients who did not develop the disease. Firstly, they were signifi cantly older. 
However, clinicians noted that diabetic subjects who developed HF were, on average, 
5.5  years younger than non-diabetic patients who developed CHF [20]. Secondly, 
patients with HF had diabetes for a  longer period of time, worse glycemic control 
(manifested by higher HbA1c), higher blood pressure and more advanced kidney 
disease than diabetic subjects without HF. Moreover, ischemic heart disease, insulin 
and metformin usage were more common in those with HF [20]. 
The most common type of HF in seniors is one with preserved ejection 
fraction (HFpEF) [16]. Studies have shown that 55% of older patients with HF have 
left  ventricular ejection fraction (LVEF) higher than 50%, and 80% of seniors have 
a normal or mildly reduced systolic function (with an LVEF of 50% ± 5%)  [16, 21]. 
Masoudi FA and other scientists have noted an association between the female gender 
and preserved ejection fraction in hospitalized elderly subjects [22].
Clinical assessment
In seniors atypical presentations of chronic heart failure is much more common 
than in younger patients. Some factors, such as cognitive defi cits, memory changes, 
anxiety, insomnia, psychosis, frailty may contribute to the  later onset of symptoms 
of the  disease [16]. Also malnutrition, limitations of exercise and sedentary lifestyles 
or comorbid diseases such as musculoskeletal or respiratory disorders, malignancies, 
immobility all have an infl uence on the  long, asymptomatic early stage of HF. Other 
signs and symptoms may result from comorbid diseases, for example, fl uid overload 
in renal disease, fatigue secondary to anemia or infections, which may complicate 
the presentations of HF (example dyspnea). Crackles or pleural eff usions may be due 
to coexistent diseases, not only with chronic heart failure. Peripheral edema may be 
connected with venous insuffi  ciency [23]. Alternative diagnoses may delay the proper 
diagnosis of HF. Th e  comorbidities can worsen or exacerbate the  course of chronic 
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heart failure. Th erefore, recognizing subtle changes in the medical history or physical 
examination of older patients is particularly important [16].
Typical symptoms of chronic heart failure in seniors are fatigue, weakness, 
dizziness and change in mental status [16]. Exertional dyspnea is not common in 
seniors because of immobility and iatrogenic factors such as a low salt diet or digoxin 
toxicity [24]. Also jugular venous distinction may be absent, despite an overload of 
fl uid [16].
More importantly, older patients may decrease their physical activities to 
compensate for their reduced effi  ciency resulting from HF. Hence careful history 
taking and inquiring about medication, fl uid intake changes and recent hospitalizations 
may have an impact on the  proper diagnostic and therapeutic decisions. Clinicians 
should be careful when treating seniors because even a slight change in drug dosage 
may have serious clinic consequence, for example, electrolyte disturbances caused by 
diuretics can lead to delirium [16].
It is recommended to evaluate heart rhythm regularly, as well as orthostatic 
changes in blood pressure, nutritional and mental status and changes in daily activities 
of patients, because subtle changes of these may be determinants of the progression of 
HF and the need to modify treatment [16].
Physiological changes in age. Echocardiographic diff erences. 
Infl uence of other diseases on the course of heart failure in older patients
Th e heart undergoes physiological and structural changes with age [25]. Some 
diseases that occur more oft en with age (for example, diabetes, chronic kidney disease, 
hypertension, obesity) may result in the  stiff ening of the  myocardium and lead to 
diastolic dysfunction, which is particularly frequent in women [9, 26]. According 
to an analysis by Ozierański K., heart failure with preserved ejection fraction, with 
a  threshold of 50% or higher, occurred more oft en in patients aged 65 years or older 
than in younger groups [9]. Some studies confi rm that HF in the  elderly results 
from ischemic or valvular heart disease [9, 10, 27]. Th e most common valvular heart 
disease in seniors with HF is aortic stenosis [9].
The frequency of atherosclerosis and arterial stiffening increase in the  aging 
population [9]. It is associated with the  progression of cardiovascular disease, 
limited physical activity and a  worse general physical condition [9]. Moreover, 
atherosclerosis results in longer hospital stays, heart rhythm disturbances and other 
complications  [28]. Th e  heart with age becomes less responsive to catecholamine 
and neurological stimulation. It is unable to increase the  strength and rate of its 
contractions [9]. Th is disability contributes to pacemaker implantation, especially 
in patients aged 65 or older [9]. Also atrial fi brillation, which is common in seniors 
with HF [29], oft en leads to stroke, especially in patients aged 75 years or older, who 
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were less frequently treated with anticoagulants, because of a higher risk of bleeding 
[9]. So, clinicians should carefully assess the  individual risk for thromboembolic and 
bleeding occurrences [29, 30].
The prevalence of chronic obstructive pulmonary disease [COPD] in older 
patients with HF is very common (about 40% of patients with HF) [31], and it is an 
independent predictor of death and hospitalization [30]. COPD and coexisting left  
ventricular dysfunction are the highest risk factors of mortality in seniors [9].
Natriuretic peptide and its use
Brain natriuretic peptide (BNP) and NT-proBNP are well-known biomarkers of 
chronic heart failure and useful in the  preliminary diagnosis of the  disease. Th ese 
biochemical markers also have prognostic value [5]. Th ey may also be a  useful 
diagnostic tool in very elderly patients (above 80 years of age) with typical signs and 
symptoms of HF in the  emergency room. BNP may be considered a  marker of an 
increased risk of cardiac morbidity and total mortality [32].
BNP above 100 pg/ml has a 76% specifi city and 90% sensitivity in the diagnosis of 
HF in patients with symptoms of heart failure [33]. BNP levels increase with age and 
the best cutoff  value for patients above 65 years of age is 250 pg/ml [34].
Th ygesen found that in patients above 75 years of age a level of NT-proBNP above 
1800 pg/ml has a 73% specifi city and 95% sensitivity in diagnosing HF in the group 
of patients with acute dyspnea [34].
Cachexia and sarcopenia and the obesity paradox
Heart failure is a  catabolic state. Cachexia is well-known in patients with end-stage 
chronic heart failure and this is a risk factor of death in this stage [35].
It is a  well-known fact that the  risk of cardiovascular diseases in obese patients 
is increased. However, in patients with HF, previous studies showed better outcomes 
of treatment in obese individuals [9, 36]. Th ere are observations that obese patients 
may have a survival benefi t in cardiovascular decompensation, such as in myocardial 
infarction or congestive heart failure [37]. According to Amundson DE obese patients 
tend to fare better aft er certain surgical procedures, for example, coronary artery 
bypass surgery. Obese men with chronic hypertensive heart disease live longer than 
men with a  normal weight [37]. Th e  mechanisms of this phenomenon, so-called 
the obesity paradox, is unclear [36]. Oga EA gives one of the probable interpretation 
of the  obesity paradox: obese patients may have a  more metabolic reserve. Th ese 
metabolic reserves have great meaning in elderly patients with HF [36].
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Adherence to therapy
Adverse eff ects of medications occur more oft en in older patients than in younger 
ones. Th is fact is because of physiologic changes. A  decrease of elasticity of 
the  cardiovascular system, higher systolic arterial blood pressure and left  ventricular 
hypertrophy, impairment of myocardial relaxation and activation of the  sympathetic 
nervous system by a  vasoconstrictor response are typical of aging patients [16, 38]. 
Maison P. and others described the  pharmacokinetic and pharmacodynamic eff ects 
of cardiovascular medication [39]. Th ey found that a  decrease in hepatic blood fl ow 
by 20–50% and a  reduction of hepatic volume by 20–30% as well as renal mass 
reduction of 25–30% and a diminution of renal blood fl ow by 1% had an impact on 
drug disposition in the organism of elderly patients [40]. In that population not only 
can the absorption of a drug be impaired, [16] but due to total body water decreasing 
and body fat increasing, the  distribution may be disturbed [40]. Consequently, there 
is a  smaller volume of distribution of digoxin and other water soluble drugs  [16]. 
Th e  change of renal function may aff ect the  clearance of many medications, such 
as  e.g., carvedilol [16]. Moreover, decreased clearance of some ACE inhibitors (such 
as enalapril or perindopril), cause stronger blood pressure-lowering eff ects  [39]. 
According to Lavan AH, more than 50% of hospitalizations resulting from adverse 
drug reactions, particularly diuretics, NSAIDs, antiplatelet, anticoagulant and 
antidiabetic drugs, can be avoided [41].
Polypragmasia leads to non-adherence to therapy, with a  non-adherence rate of 
35% in patients taking four or more medications [16, 42]. Non-adherence with diet 
or pharmacotherapy in patients with chronic heart failure is a  common factor that 
contributes to decompensation of 42% of patients in older age [16]. Complexity 
of the  treatment regimen, the  adverse eff ects of drugs and a  patient’s perception 
of the  necessity of treatment also affect a  patient’s compliance [16]. The  open 
communication between the  patient and his/her doctor resulting partnership, 
the process in which the patient is in the centre of all medical decisions can contribute 
to a stronger commitment of the patient to the care plan [16].
Palliative care
In advanced stages of heart failure, when aggressive treatment becomes ineff ective, 
palliative care should be implemented [16]. Th e  aim of palliative care is to ensure 
the  highest possible quality of life for the  patient, for as long as possible [16]. Th is 
engages a multidisciplinary approach and the team includes a main physician, nursing 
team, pastoral care support and other support staff  [16]. Focused treatment of specifi c 
symptoms, such as severe dyspnea, can help to alleviate patients’ discomfort through 
a  complex therapy [16]. Th is also includes treatment of anxiety and depression of 
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the patient, and oft en of the family members [16]. Th e other aspect of palliative care in 
the  terminal stage is the  targeted therapy of specifi c symptoms, such as constipation, 
anorexia or sleep disorders [43]. Narcotics, benzodiazepines and sedatives may be 
used in the treatment of pain and anxiety [44]. 
In order to avoid aggressive and futile or uncomfortable interventions in 
the  critical stage, instituted hospice services should be introduced early [45]. Many 
older patients prefer to die in their own home. If family and medical support is 
available, it should be taken into consideration [46].
Conclusion
Chronic heart failure is widespread in the  population of older patients [16]. Some 
factors, such as structural, biochemical, clinical and psychological aspects are 
unique to patients in older age [16]. According to Ozierański K. and others, seniors 
suff ering from heart failure diff ered from young patients in terms of the  long-term 
outcome and prognostic factors [9]. Chronic obstructive pulmonary disease in older 
patients with HF is very common and is an independent predictor of death and 
hospitalization  [47,  48]. Some factors have protective prognostic eff ects in patients 
aged 65 years or older: physical activity, higher potassium level on admission and 
beta-blocker use at discharge from the hospital [16].
Careful medical history recording, including medications and regular physical 
examinations are particularly important when treating patients suff ering from chronic 
heart failure.
The main goal of treatment in the  end-stage of life should be maximizing 
the patient’s comfort [16]. 
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